Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch

BMC Neurology

Volumn 10, Issue , 2010, Pages

  Högl, Birgit ^a   Oertel, Wolfgang H ^b   Stiasny Kolster, Karin ^b   Geisler, Peter ^c   Beneš, Heike ^d   García Borreguero, Diego ^e   Trenkwalder, Claudia ^f,g   Poewe, Werner ^a   Schollmayer, Erwin ^h   Kohnen, Ralf ^i,j  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e SLEEP RESEARCH INSTITUTE   (Spain)

^f Paracelsus Elena Hospital   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h Schwarz Pharma AG   (Germany)

ⁱ Research Pharmaceutical Services Inc   (United States)

^j UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROTIGOTINE; DOPAMINE RECEPTOR STIMULATING AGENT; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; APPLICATION SITE REACTION; ARTICLE; BACKACHE; BODY WEIGHT; BRONCHITIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC SIDE EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRURITUS; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SLEEP DISORDER; TRANSDERMAL PATCH; TREATMENT DURATION; TREATMENT WITHDRAWAL; VITAL SIGN; AGED; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE;

ADULT; AGED; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RESTLESS LEGS SYNDROME; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH; YOUNG ADULT;

EID: 77957157133     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-10-86     Document Type: Article

References (26)

1. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J, . Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119. 10.1016/S1389-9457(03)00010-8, 14592341, Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group.
2. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol 2005, 4:465-475. 10.1016/S1474-4422(05)70139-3, 16033689.
3. Kushida C, Martin M, Nikam P, Blaisdell B, Wallenstein G, Ferini-Strambi L, Ware JE. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007, 16:617-624. 10.1007/s11136-006-9142-8, 17268935.
4. Oertel WH, Trenkwalder C, Zucconi M, Benes H, Borreguero DG, Bassetti C, Partinen M, Ferini-Strambi L, Stiasny-Kolster K. State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord 2007, 22(Suppl 18):S466-475. 10.1002/mds.21545, 17516455.
5. Hening WA. Current guidelines and standards of practice for restless legs syndrome. Am J Med 2007, 120(1A):S22-S27. 10.1016/j.amjmed.2006.11.004, 17198767.
6. Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Stiasny-Kolster K, Sampaio C. Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice. Mov Disord 2008, 23:2267-2302. 10.1002/mds.22254, 18925578.
7. Partinen M, Hirvonen K, Jama L, Alakuijala A, Hublin C, Tamminen I, Koester J, Reess J. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study). Sleep Med 2008, 9:537-541. 10.1016/j.sleep.2007.12.004, 18276187.
8. Garcia-Borreguero D, Grunstein R, Sridhar G, Dreykluft T, Montagna P, Dom R, Lainey E, Moorat A, Roberts J. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 2007, 8:742-752. 10.1016/j.sleep.2006.09.009, 17512789.
9. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn-Schmiedeberg's Arch Pharmacol 2009, 379:73-86.
10. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007, 68:272-276. 10.1212/01.wnl.0000252355.79284.22, 17202432.
11. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, . SP 515 Investigators Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurology 2007, 6:513-520. 10.1016/S1474-4422(07)70108-4, 17509486, SP 515 Investigators.
12. Stiasny-Kolster K, Kohnen R, Schollmayer E, Möller JC, Oertel WH, . The Rotigotine SP 666 Study Group Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004, 19:1432-1438. 10.1002/mds.20251, 15390055, The Rotigotine SP 666 Study Group.
13. Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Högl B, Saletu B, Trenkwalder C, Sommerville KW, Schollmayer E, Kohnen R, Stiasny-Kolster K, . Rotigotine SP 709 Study Group Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008, 9:228-239. 10.1016/j.sleep.2007.04.010, 17553743, Rotigotine SP 709 Study Group.
14. Trenkwalder C, Benes H, Poewe W, Oertel WH, Garcia-Borreguero D, de Weerd AW, Ferini-Strambi L, Montagna P, Odin P, Stiasny-Kolster K, Högl B, Chaudhuri KR, Partinen M, Schollmayer E, Kohnen R, . SP790 Study Group Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008, 7:595-604. 10.1016/S1474-4422(08)70112-1, 18515185, SP790 Study Group.
15. Hening WA. Effective treatment of idiopathic RLS with 24-hour rotigotine transdermal patch: results of a 6-month, multicenter, double-blind, placebo-controlled trial in the USA. Eur J Neurol 2008, 15(Suppl 3):111. (abstract P1297).
16. Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Högl B, Trenkwalder C, Tacken I, Schollmayer E, Kohnen R, Stiasny-Kolster K, . Rotigotine SP710 Study Group One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med 2008, 9:865-873. 10.1016/j.sleep.2008.04.012, 18753003, Rotigotine SP710 Study Group.
17. National Institute of Mental Health 028 CGI. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology 1976, 217-222. Rockville, MD: National Institute of Mental Health, Guy W, National Institute of Mental Health.
18. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:540-545.
19. The International Restless Legs Syndrome Study Group Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003, 4:121-132. 10.1016/S1389-9457(02)00258-7, 14592342, The International Restless Legs Syndrome Study Group.
20. Kohnen R, Stiasny-Kolster K, Oertel WH, Beneš H, Trenkwalder C. Severity Rating of Restless Legs Syndrome: validation of the RLS-6 scales. Sleep 2004, 27(Abstract Suppl):A342.
21. Kohnen R, Beneš H, Heinrich CR, Kurella B. Development of the disease-specific Restless Legs Syndrome Quality of Life (RLS-QoL) questionnaire. Mov Disord 2002, 17(Suppl 5). P743Abs.
22. Beneš H, Heinrich CR, Ueberall MA, Kohnen R. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 2004, 27:674-682.
23. Trenkwalder C, Benes H, Grote L, Happe S, Högl B, Mathis J, Saletu-Zyhlarz GM, Kohnen R, . CALDIR Study Group Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 2007, 22:696-703. 10.1002/mds.21401, 17274039, CALDIR Study Group.
24. García-Borreguero D, Allen RP, Benes H, Earley C, Happe S, Högl B, Kohnen R, Paulus W, Rye D, Winkelmann J. Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord 2007, 22(Suppl 18):S476-484. 10.1002/mds.21610, 17580331.
25. Vaillant L, Biette S, Machet L, Constans T, Monpere C. Skin acceptance of transcutaneous nitroglycerin patches: a prospective study of 33 patients. Contact Dermatitis 1990, 23:142-145. 10.1111/j.1600-0536.1990.tb04774.x, 2126502.
26. Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 1998, 15:168-175. 10.1016/S0885-3924(97)00361-8, 9564118.